Heplisav-B™ [hepatitis B vaccine, recombinant (adjuvanted)], was approved by the . Food and Drug Administration (FDA) on Nov. 9, 2017, for preventing all subtypes of hepatitis B. It includes a Toll-like Receptor (TLR) 9 agonist that increases immune response to the hepatitis B surface antigen in it. Indicated for adults, it will be given as two intramuscular (IM) injections spaced one month apart. Currently available hepatitis B vaccines require more doses to be administered over longer times. Additionally, in clinical trials, Heplisav-B was effective for higher percentages of participants receiving it than an already available vaccine was. Hepatitis B, a highly contagious, incurable viral infection of the liver, can be sexually transmitted or acquired from contact with blood infected with it. Untreated, it can result in cirrhosis, cancer or death. Because children are vaccinated against hepatitis B, nearly all new diagnoses in the United States – about 3,400 acute cases and 14,500 chronic cases in 2015 – are among adults. The . Centers for Disease Control and Prevention (CDC) recommends hepatitis B vaccinations for adults who have diabetes and those who may be at higher risk through their lifestyles, occupations or travel. Dynavax, Heplisav-B’s manufacturer, expects to launch Heplisav-B in the first quarter of 2018. Its full prescribing information is available here .
New Anti-Emetic Approved